These results suggest that the peptide must be loaded directly on the semiallogeneic BMDCs to stimulate cytotoxic CD8+ T cells, and then the alloantigen-specific CD4+ T cell response can synergistically work to enhance CD8+ T cell suppression of tumor growth. Here, CD8A is linked to neoplasm.